618 results on '"Henze, Günter"'
Search Results
2. A Single Dose of PEG-Asparaginase at the Beginning of Induction Not Only Accelerates MRD Clearance but Also Improves Long-Term Outcome in Children with B-Lineage ALL
3. Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow–Berlin 2002
4. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial
5. Supplementary Methods from Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB
6. Supplementary Figure 2 from Expression of Late Cell Cycle Genes and an Increased Proliferative Capacity Characterize Very Early Relapse of Childhood Acute Lymphoblastic Leukemia
7. Supplementary Table 1 from Expression of Late Cell Cycle Genes and an Increased Proliferative Capacity Characterize Very Early Relapse of Childhood Acute Lymphoblastic Leukemia
8. Supplementary Figure 1 from Expression of Late Cell Cycle Genes and an Increased Proliferative Capacity Characterize Very Early Relapse of Childhood Acute Lymphoblastic Leukemia
9. Supplementary Tables 1 - 8 from Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB
10. Supplementary Figures 1 - 13 from Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB
11. Supplementary Figure Legend from Synergistic Activity of Bortezomib and HDACi in Preclinical Models of B-cell Precursor Acute Lymphoblastic Leukemia via Modulation of p53, PI3K/AKT, and NF-κB
12. Management of tumor rupture and abdominal compartment syndrome in an infant with bilateral high risk stage 4 neuroblastoma: A case report
13. X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL
14. B-cell precursor leukemias with MYC-rearrangement come into the limelight
15. Additional file 1 of Integrative medicine during the intensive phase of chemotherapy in pediatric oncology in Germany: a randomized controlled trial with 5-year follow up
16. Siblings of children with cancer—the price they pay to function
17. X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL.
18. Explorative analyses on the value of interim PET for prediction of response in pediatric and adolescent non-Hodgkin lymphoma patients
19. Impact of chemotherapy and radiotherapy in childhood on fertility in adulthood: the FeCt—survey of childhood cancer survivors in Germany
20. Siblings of children with cancer—the price they pay to function
21. THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents
22. The rare-earth yttrium complex [YR(mtbmp)(thf)] triggers apoptosis via the extrinsic pathway and overcomes multiple drug resistance in leukemic cells
23. Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma
24. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters
25. Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia
26. Use of positron emission tomography for staging, preoperative response assessment and posttherapeutic evaluation in children with Wilms tumour
27. Induction of apoptosis by enediyne antibiotic calicheamicin ϑII proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner
28. Relapsed acute lymphoblastic leukemia
29. Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome
30. Can anthocyanins improve maintenance therapy of Ph+ acute lymphoblastic leukaemia?
31. PEG-asparaginase (Oncaspar) 2500 U/m2 BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols
32. Desmethylxanthohumol from Hops, Chemistry and Biological Effects
33. List of Contributors
34. SUV-measurements and patient-specific corrections in pediatric Hodgkin-lymphoma: Is there a benefit for PPV in early response assessment by FDG-PET?
35. Autologous Purified Peripheral Blood Stem Cell Transplantation Compare To Chemotherapy in Childhood Acute Lymphoblastic Leukemia After Low-Risk Relapse
36. Adverse events associated with the use of complementary and alternative medicine in children
37. XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL†
38. Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses
39. Serum levels of Midkine in children and adolescents without malignant disease
40. Rezidive der akuten lymphoblastischen Leukämie
41. Loss of Fine Motor Function Correlates With Ataxia And Decline of Cognition in Cerebellar Tumor Survivors
42. Apoptosis-inducing activity of Helleborus niger in ALL and AML
43. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria – A population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group
44. Early postinduction intensification therapy is essential in childhood acute lymphoblastic leukemia
45. Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics
46. Adsorptive stripping voltammetric determination of vanadium as chloranilic acid complex
47. Determination of adenine, caffeine, theophylline and theobromine by HPLC with amperometric detection
48. Voltammetric determination of Ioxynil and 2-methyl-3-nitroaniline using C18 modified carbon paste electrodes
49. Response to Subcutaneous Therapy With Mistletoe in Recurrent Multisystem Langerhans Cell Histiocytosis
50. Prenatal manifestation of pancytopenia in Pearson marrow-pancreas syndrome caused by a mitochondrial DNA deletion
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.